Associated Papers
Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer.
Zhang L et al.
Molecular Oncology, 2022
35971249 (PubMed )
Supplement: MOL2-16-3689-s005.xlsx › Table_S3
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Lee JH et al.
Cancer Medicine, 2021
Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer.
Pennycuick A et al.
International Journal of Clinical Practice, 2012
Select a paper to view details